Endometrial Regenerative Cells
MediStem is dedicated to commercialization of the Endometrial Regenerative Cell (ERC), a universal donor stem cell product that does not require matching with the recipient. ERC have the ability to become brain, lung, liver, bone, cartilage, pancreatic, fat, muscle, heart, and blood vessel tissue.
MediStem has discovered and filed patents on a novel type of stem cell, the Endometrial Regenerative Cell (ERC). This cell appears to have all the major attributes desirable in an ideal cellular therapy: a) Grows well and is scalable for mass production; b) Can be administered intravenously because it selectively homes to damaged tissue; c) Does not require matching with the recipient, allowing for generation of standardized batches that can be shipped to the point of care.
Medistem Inc. Annual Letter to Shareholders
December 31, 2011 By Medistem Inc. Leave a Comment
SAN DIEGO, CA--(Marketwire -12/31/11)- Medistem Inc. (Pinksheets: MEDS.PK - News) today issues the following letter to shareholders. Dear Fellow Shareholders, The last year has been remarkable for Medistem: new investors, new collaborators, and an FDA approval. The FDA approval is for a 15 patient study investigating the … [Read More]
Investor Updates
For investor updates, please fill in your information below. You will only receive Medistem Inc. investment related information.